Preliminary results in Duchenne muscular dystrophy trial indicate promise for allogeneic cardiosphere-derived cells
Capricor Therapeutics presented six month data from their allogeneic cell therapy at the 2017 Parent Project Muscular Dystrophy Annual Connect Conference.
In a poster presented at the 2017 Parent Project Muscular Dystrophy Annual Connect Conference (29 June–2 July, Chicago, IL, USA), Capricor Therapeutics (CA, USA) revealed encouraging six month results from their Phase I/II HOPE-Duchenne clinical trial of CAP-1002 to treat Duchenne muscular dystrophy .
In this first trial, CAP-1002 was evaluated in young men and boys that have Duchenne muscular dystrophy with significant cardiac involvement. Subjects received CAP-1002, allogeneic cardiosphere-derived cells, intravenously into all three coronary arteries. CAP-1002 was found to improve cardiac systolic wall thickening and improve Performance of Upper Limb (mid-level).
Subject to regulatory approval, Capricor expects to launch its’ next trial of CAP-1002 in the second half of 2017.